The COVID-19 pandemic had a significant impact on health care delivery. We used the Surveillance, Epidemiology, and End Results (SEER) data to assess changes in 1-year relative survival and competing risk probabilities of cancer and non-cancer death for patients diagnosed in 2018 Q2 (pre-pandemic) and 2020 Q2 (pandemic). For all cancer sites combined, 1-year relative survival declined from 82.3% in 2018 Q2 to 77.5% in 2020 Q2, with the steepest declines seen in stomach, leukemia, and liver cancers. However, survival improved nearing pre-pandemic levels during 2020 Q3. Competing risk survival measures revealed that the decline in 1-year survival was driven by increases in both the probability of dying of cancer (rising from 15.4% to 19.2%) and of other causes, including COVID (rising from 3.8% to 5.2%). The pandemic led to significant declines in survival and increased mortality from both cancer and other causes for patients diagnosed in 2020 Q2.

中文翻译：

---

评估 COVID-19 大流行对美国 1 年癌症生存率的影响


COVID-19 大流行对医疗保健服务产生了重大影响。我们使用监测、流行病学和最终结果 （SEER） 数据来评估 2018 年第二季度（大流行前）和 2020 年第二季度（大流行）诊断的患者的 1 年相对生存率以及癌症和非癌症死亡竞争风险概率的变化。对于所有癌症部位，1 年相对生存率从 2018 年第二季度的 82.3% 下降到 2020 年第二季度的 77.5%，其中胃癌、白血病和肝癌的下降幅度最大。然而，在 2020 年第三季度，生存率提高到接近疫情前的水平。竞争性风险生存指标显示，1 年生存率的下降是由死于癌症（从 15.4% 上升到 19.2%）和其他原因（包括 COVID）（从 3.8% 上升到 5.2%）的概率增加驱动的。大流行导致 2020 年第二季度诊断的患者的生存率显着下降，癌症和其他原因导致的死亡率增加。